Across TCGA pan-cancer cohorts, SNX32 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SNX32 data layer compared with 26 for mass-spec protein and 4 for mutation status.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher SNX32 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SNX32 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.
GBM and PDAC are the cancer types where SNX32 mass-spec protein most reproducibly stratifies survival.